BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 2350532)

  • 1. Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects.
    Andersson T; Andrén K; Cederberg C; Lagerström PO; Lundborg P; Skånberg I
    Br J Clin Pharmacol; 1990 May; 29(5):557-63. PubMed ID: 2350532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral bioavailability of omeprazole before and after chronic therapy in patients with duodenal ulcer.
    Ching MS; Mihaly GW; Angus PW; Morgan DJ; Devenish-Meares S; Yeomans ND; Smallwood RA
    Br J Clin Pharmacol; 1991 Feb; 31(2):166-70. PubMed ID: 2049231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of various single intravenous and oral doses of omeprazole.
    Andersson T; Cederberg C; Regårdh CG; Skånberg I
    Eur J Clin Pharmacol; 1990; 39(2):195-7. PubMed ID: 2253676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacokinetics of omeprazole in humans--a study of single intravenous and oral doses.
    Regårdh CG; Andersson T; Lagerström PO; Lundborg P; Skånberg I
    Ther Drug Monit; 1990 Mar; 12(2):163-72. PubMed ID: 2315973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of acid secretory status on absorption of omeprazole from enteric coated granules.
    Andersson T; Bergstrand R; Cederberg C
    Br J Clin Pharmacol; 1991 Mar; 31(3):275-8. PubMed ID: 2054268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of once daily intravenous and oral omeprazole on 24-hour intragastric acidity in healthy subjects.
    Cederberg C; Röhss K; Lundborg P; Olbe L
    Scand J Gastroenterol; 1993 Feb; 28(2):179-84. PubMed ID: 8441912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg) or enteric-coated aspirin 325 mg + enteric-coated omeprazole 40 mg - a randomised, phase 1, crossover study.
    Miner PB; Fort JG; Zhang Y
    Aliment Pharmacol Ther; 2013 Jul; 38(1):62-71. PubMed ID: 23692061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative bioavailability of two enteric-coated capsules of omeprazole in healthy volunteers.
    Garg SK; Chugh Y; Tripathi SK; Kumar N; Sharma PL
    Int J Clin Pharmacol Ther Toxicol; 1993 Feb; 31(2):96-9. PubMed ID: 8458683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic study of omeprazole in elderly healthy volunteers.
    Landahl S; Andersson T; Larsson M; Lernfeldt B; Lundborg P; Regårdh CG; Sixt E; Skånberg I
    Clin Pharmacokinet; 1992 Dec; 23(6):469-76. PubMed ID: 1458764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omeprazole: pharmacokinetics and metabolism in man.
    Cederberg C; Andersson T; Skånberg I
    Scand J Gastroenterol Suppl; 1989; 166():33-40; discussion 41-2. PubMed ID: 2690330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects.
    Hassan-Alin M; Andersson T; Niazi M; Röhss K
    Eur J Clin Pharmacol; 2005 Jan; 60(11):779-84. PubMed ID: 15578172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioavailability and efficacy of omeprazole given orally and by nasogastric tube.
    Larson C; Cavuto NJ; Flockhart DA; Weinberg RB
    Dig Dis Sci; 1996 Mar; 41(3):475-9. PubMed ID: 8617118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of single and repeated intravenous doses of omeprazole on pentagastrin stimulated gastric acid secretion and pharmacokinetics in man.
    Jansen JB; Lundborg P; Baak LC; Greve J; Ohman M; Stöver C; Röhss K; Lamers CB
    Gut; 1988 Jan; 29(1):75-80. PubMed ID: 3343017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of oral omeprazole in llamas.
    Poulsen KP; Smith GW; Davis JL; Papich MG
    J Vet Pharmacol Ther; 2005 Dec; 28(6):539-43. PubMed ID: 16343286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of [14C]omeprazole in patients with liver cirrhosis.
    Andersson T; Olsson R; Regårdh CG; Skånberg I
    Clin Pharmacokinet; 1993 Jan; 24(1):71-8. PubMed ID: 8448974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of soybean administration on the pharmacokinetics of carbamazepine and omeprazole in rats.
    Singh D; Asad M
    Fundam Clin Pharmacol; 2010 Jun; 24(3):351-5. PubMed ID: 19682087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonencapsulated, intact omeprazole granules effectively suppress intragastric acidity when administered via a gastrostomy.
    Sharma VK; Heinzelmann EJ; Steinberg EN; Vasudeva R; Howden CW
    Am J Gastroenterol; 1997 May; 92(5):848-51. PubMed ID: 9149199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of intravenous, plain oral and enteric-coated oral omeprazole in the horse.
    Sykes BW; Underwood C; McGowan CM; Mills PC
    J Vet Pharmacol Ther; 2015 Apr; 38(2):130-6. PubMed ID: 25271390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-pass metabolism of omeprazole in rats.
    Watanabe K; Furuno K; Eto K; Oishi R; Gomita Y
    J Pharm Sci; 1994 Aug; 83(8):1131-4. PubMed ID: 7983597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antisecretory effect and oral pharmacokinetics following low dose omeprazole in man.
    Howden CW; Forrest JA; Meredith PA; Reid JL
    Br J Clin Pharmacol; 1985 Aug; 20(2):137-9. PubMed ID: 3929808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.